Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference
Business Wire India Samsung Bioepis plans to secure 20 biosimilars in its products and pipeline by 2030 The new pipeline will include dupilumab, guselkumab, ixekizumab, fam-trastuzumab deruxtecan-nxki, vedolizumab, and ocrelizumab,…